Opus Genetics Stock Net Income
| IRD Stock | 2.12 0.11 5.47% |
Fundamental analysis of Opus Genetics allows traders to better anticipate movements in Opus Genetics' stock price by examining its financial health and performance throughout various phases of its business cycle.
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Opus Genetics Company Net Income Analysis
Opus Genetics' Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Opus Genetics Net Income | (57.53 M) |
Most of Opus Genetics' fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Opus Genetics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Opus Genetics reported net income of (57.53 Million). This is 116.86% lower than that of the Pharmaceuticals sector and 182.13% lower than that of the Health Care industry. The net income for all United States stocks is 110.08% higher than that of the company.
Opus Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Opus Genetics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Opus Genetics could also be used in its relative valuation, which is a method of valuing Opus Genetics by comparing valuation metrics of similar companies.Opus Genetics is currently under evaluation in net income category among its peers.
Opus Fundamentals
| Return On Equity | -3.39 | ||||
| Return On Asset | -0.61 | ||||
| Operating Margin | (2.70) % | ||||
| Current Valuation | 108.87 M | ||||
| Shares Outstanding | 68.96 M | ||||
| Shares Owned By Insiders | 14.17 % | ||||
| Shares Owned By Institutions | 27.60 % | ||||
| Number Of Shares Shorted | 635.92 K | ||||
| Price To Book | 23.23 X | ||||
| Price To Sales | 9.47 X | ||||
| Revenue | 10.99 M | ||||
| Gross Profit | (12.79 M) | ||||
| EBITDA | (57.52 M) | ||||
| Net Income | (57.53 M) | ||||
| Total Debt | 18.84 M | ||||
| Book Value Per Share | 0.09 X | ||||
| Cash Flow From Operations | (25.58 M) | ||||
| Short Ratio | 1.09 X | ||||
| Earnings Per Share | (1.86) X | ||||
| Target Price | 7.8 | ||||
| Number Of Employees | 18 | ||||
| Beta | 0.42 | ||||
| Market Capitalization | 138.62 M | ||||
| Total Asset | 36.86 M | ||||
| Retained Earnings | (139 M) | ||||
| Working Capital | 25.32 M | ||||
| Net Asset | 36.86 M |
About Opus Genetics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Opus Genetics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Opus Genetics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Opus Genetics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| JBL | Jabil Circuit | |
| MRK | Merck Company | |
| AMGN | Amgen Inc |
Check out Opus Genetics Piotroski F Score and Opus Genetics Altman Z Score analysis. For information on how to trade Opus Stock refer to our How to Trade Opus Stock guide.You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Opus Genetics. If investors know Opus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Opus Genetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Opus Genetics is measured differently than its book value, which is the value of Opus that is recorded on the company's balance sheet. Investors also form their own opinion of Opus Genetics' value that differs from its market value or its book value, called intrinsic value, which is Opus Genetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Opus Genetics' market value can be influenced by many factors that don't directly affect Opus Genetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Opus Genetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Opus Genetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Opus Genetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.